{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:53:05Z","timestamp":1777297985266,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020689","name":"Nebraska Water Center, Water for Food Daugherty Global Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020689","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clinthera.2023.06.011","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T15:44:23Z","timestamp":1689176663000},"page":"1099-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inclisiran for the Treatment of Hyperlipidemia and for Atherosclerotic Cardiovascular Disease Risk Reduction: A Narrative Review"],"prefix":"10.1016","volume":"45","author":[{"given":"Kevin","family":"Cowart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerica","family":"Singleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-5034","authenticated-orcid":false,"given":"Nicholas W.","family":"Carris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.06.011_bib0001","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11892-019-1178-6","article-title":"Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition","volume":"19","author":"Rosenblit","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0003","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ahj.2019.05.009","article-title":"Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: results from the Patient and Provider Assessment of Lipid Management (PALM) registry","volume":"214","author":"Nanna","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0005","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2023.06.011_bib0006","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0007","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11886-011-0221-2","article-title":"Predictors of statin adherence","volume":"13","author":"Mauskop","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/VHRM.S158641","article-title":"Nonadherence to statins: individualized intervention strategies outside the pill box","volume":"14","author":"Lansberg","year":"2018","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0009","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0010","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s11606-008-0636-7","article-title":"Prevalence of musculoskeletal pain and statin use","volume":"23","author":"Buettner","year":"2008","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0011","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0012","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11886-022-01729-x","article-title":"SAMSON and the nocebo effect: management of statin intolerance","volume":"24","author":"Krishnamurthy","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0013","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/FJC.0000000000001053","article-title":"Inclisiran: A novel agent for lowering apolipoprotein B\u2013containing lipoproteins","volume":"78","author":"Warden","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0014","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0015","series-title":"Leqvio (inclisiran) [package insert]","year":"2021"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0016","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/phar.2635","article-title":"Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD","volume":"41","author":"Talasaz","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-022-01542-4","article-title":"PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis","volume":"21","author":"Wang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100294","article-title":"The impact of lipid-lowering medications on coronary artery plaque characteristics","volume":"8","author":"Pulipati","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0019","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of Phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0022","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0023","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","article-title":"Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis","volume":"22","author":"Desai","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0024","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2021.03.042","article-title":"A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia","volume":"325","author":"Brandts","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/03007995.2022.2049164","article-title":"Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis","volume":"38","author":"Burnett","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025551","article-title":"Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol","volume":"11","author":"Toth","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0027","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/fca-2018-0067","article-title":"Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program","volume":"14","author":"Stoekenbroek","year":"2018","journal-title":"Future Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0028","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7196\/SAMJ.2022.v112i6.16253","article-title":"Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION Phase III clinical trials","volume":"112","author":"Raal","year":"2022","journal-title":"S Afr Med J"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0029","article-title":"Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 randomized controlled trials","author":"Koenig","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0030","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0031","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40273-022-01152-8","article-title":"Cost-effectiveness, burden of disease and budget impact of inclisiran: dynamic cohort modelling of a real-world population with cardiovascular disease","volume":"40","author":"Galactionova","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0032","first-page":"961","article-title":"The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD","volume":"27","author":"Agboola","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0033","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","article-title":"Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1","volume":"117","author":"Landmesser","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0034","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","article-title":"Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment","volume":"16","author":"Kallend","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0035","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0036","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0037","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.06.011_bib41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic acid: for whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0038","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jacl.2022.10.009","article-title":"Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States lipid clinic","volume":"17","author":"Chiou","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0039","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","article-title":"Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy","volume":"2","author":"Navar","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.011_bib0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019331","article-title":"Adoption of PCSK9 inhibitors among patients with atherosclerotic disease","volume":"10","author":"Dayoub","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:02:27Z","timestamp":1758963747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823002059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0149291823002059"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.06.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inclisiran for the Treatment of Hyperlipidemia and for Atherosclerotic Cardiovascular Disease Risk Reduction: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}